Boston Partners’s Takeda Pharmaceutical TAK Stock Holding History

Boston Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36M	Sell	84,903 -30,619	-27%	-$507K	﹤0.01%	645
2026 Q1	$2.14M	Buy	115,522 +21,812	+23%	+$383K	﹤0.01%	569
2025 Q4	$1.46M	Sell	93,710 -24,244	-21%	-$347K	﹤0.01%	596
2025 Q3	$1.73M	Buy	117,954 +12,219	+12%	+$181K	﹤0.01%	580
2025 Q2	$1.63M	Sell	105,735 -26,372	-20%	-$390K	﹤0.01%	555
2025 Q1	$1.96M	Buy	132,107 +63,024	+91%	+$883K	﹤0.01%	497
2024 Q4	$915K	Buy	+69,083	New	+$949K	﹤0.01%	579

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Boston Partners's TAK Position: Q2 2026 in Review

Boston Partners reduced its Takeda Pharmaceutical (TAK) stake by 27% in Q2 2026, selling an estimated $507K and leaving 84,903 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #645.

Boston Partners first reported a position in TAK in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.14M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Boston Partners held 84,903 shares of Takeda Pharmaceutical worth $1.36M as of Q2 2026.
Boston Partners sold 30,619 Takeda Pharmaceutical shares in Q2 2026, an estimated $507K.
Takeda Pharmaceutical made up ﹤0.01% of Boston Partners's portfolio in Q2 2026, its #645 holding.
Boston Partners first reported a position in Takeda Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
Boston Partners's Takeda Pharmaceutical position peaked at $2.14M in Q1 2026.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.